It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are ...

Key Takeaways UNH shares rose 4% post mixed Q4 results, with EPS beating estimates and revenues missing expectations.UnitedHealth expects a 2026 medical care ratio near 88.8%, reflecting improved cost control versus last year.UnitedHealth projects a 21% cut in 2026 Medicaid membership, raising margin concerns. Shares of UnitedHealth Group Incorporated (UNH) rose 4% during the last trading session at the bourses, following its mixed fourth-quarter 2025 results on Jan. 27, 2026. Higher-than-expected operating ...

CytoMed Therapeutics (GDTC) issued a statement to address recent statements containing “inaccurate and misleading” claims regarding the Company’s research programs, clinical progress, and operations.The company said, ” CytoMed categorically rejects such claims which have no basis. Certain statements circulating publicly mis-characterize the Company’s scientific focus, development status, and regulatory standing. Please refer to recent announcements by the Company on our progress. CytoMed’s research is focu ...

Core Viewpoint - Regenxbio (RGNX) experienced a significant premarket selloff of approximately 30% following the FDA's announcement of a clinical hold on RGX-111 for Hurler syndrome and RGX-121 for Hunter syndrome, indicating a high level of surprise in the market regarding this news [1] Group 1 - Leerink considers the market reaction to be an "overreaction," suggesting that the financial impact of the Hunter and Hurler studies on the overall value of Regenxbio shares is modest [1] - The analyst views the current share price as a buying opportunity, maintaining an Outperform rating on Regenxbio shares [1]

Core Insights - AlphaTON Capital Corp. reported $24.5 million in assets, with $11 million in cash and no debt or convertible securities, indicating a strong financial position [1][5] - The company has 23.4 million shares outstanding and has made a $4 million deposit towards acquiring 576 Nvidia B300 GPUs for AI revenue production [5] - AlphaTON is focused on scaling the Telegram super-app, targeting an addressable market of one billion monthly active users, while managing a strategic reserve of digital assets [2] Financial Position - Total assets amount to $24.5 million [5] - Cash reserves stand at $11 million [5] - The company has no outstanding debt or convertible securities, reflecting a solid balance sheet [5] Share Structure - AlphaTON has 23.4 million shares outstanding, which provides insight into its market capitalization and shareholder structure [5] Strategic Investments - The company has made a $4 million deposit for Nvidia B300 GPUs, which are intended for AI revenue production, indicating a commitment to technological advancement [5] - AlphaTON's strategy includes direct digital asset acquisition, validator operations, and investments in decentralized finance protocols and gaming platforms [2] Leadership and Governance - The company is led by CEO Brittany Kaiser, Executive Chairman Enzo Villani, and Chief Business Development Officer Yury Mitin, emphasizing a strong management team [2]

Core Insights - Biogen has received FDA Breakthrough Therapy designation for its investigational drug litifilimab (BIIB059) aimed at treating cutaneous lupus erythematosus (CLE) [1][5] Group 1: FDA Breakthrough Therapy Designation - The FDA's Breakthrough Therapy designation accelerates the development and review of drugs for serious conditions, granted when early clinical evidence indicates significant improvement over existing treatments [2] - This designation provides drugs with enhanced guidance and support from senior FDA management [2] Group 2: Clinical Evidence and Current Treatments - The FDA's decision was backed by evidence from the phase II LILAC study, which showed that litifilimab significantly reduced skin disease activity in CLE patients compared to placebo [3][5] - Current treatments for CLE, such as topical steroids and immunosuppressants, primarily manage symptoms without modifying disease progression [3] Group 3: Ongoing Studies and Future Prospects - Biogen is conducting a phase III AMETHYST study for litifilimab, with data expected in 2027, alongside two other studies for systemic lupus erythematosus (SLE) [7] - The company has additional late-stage candidates in its immunology pipeline, including dapirolizumab pegol for active SLE and felzartamab for multiple indications [8][9] Group 4: Strategic Partnerships - Biogen has entered a research agreement with Dayra Therapeutics to enhance its immunology pipeline with a new class of oral therapies, aiming to improve patient convenience and adherence [10][12]

Core Viewpoint - Vertex Pharmaceuticals is positioned for significant growth in 2026 due to several catalysts and potential regulatory advancements, despite having underperformed compared to the S&P 500 last year [1] Group 1: Late-Stage Pipeline - Vertex Pharmaceuticals has a strategy focused on developing medicines for high unmet needs, having dominated the cystic fibrosis market for over a decade [2] - The late-stage pipeline includes zimislecel for type 1 diabetes, inaxaplin for APOL-1-mediated kidney disease, and povetacicept for IgA nephropathy, all of which could lead to significant breakthroughs [2][4] - Zimislecel has shown promise in clinical trials by restoring insulin-producing capacity or reducing insulin dependence, with potential approval applications this year [3] - Inaxaplin is in a phase 2/3 trial, with plans for an interim analysis and possible accelerated approval if results are positive [3] - Povetacicept also aims for accelerated approval based on interim analysis results from its late-stage study [4] Group 2: Financial Outlook - Vertex Pharmaceuticals is expected to maintain strong financial results, with ongoing market opportunities in cystic fibrosis and the launch of Journavx, a pain medicine [5] - Casgevy, a gene-editing therapy for rare blood diseases, is anticipated to contribute modestly to financial results [5] - The company has additional pipeline candidates, although it may encounter clinical setbacks similar to those experienced last year [5]

FDA assigns Prescription Drug User Fee Act (PDUFA) target date of June 29, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) ...

Over the past five years, Novavax (NASDAQ: NVAX), a vaccine maker, lost more than 90% of its market value. Though it succeeded in its goal of launching a coronavirus vaccine, the biotech did so much later than some anticipated and struggled to keep its sales competitive with the market leaders in that niche. However, Novavax has made several moves in recent years that could help it bounce back. The company's shares are already up by 28% in 2026 after it announced a deal with a pharmaceutical giant. With ...

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose material adverse facts concerning its Phase 3 PALISADE-3 trial study of fasedienol, an ...